ZarkusGhasiri

Humans can develop PRCA in response to ESAs (esp. Epo) as well, but I assume the risk of PRCA is much higher in nonhuman species since Epogen is simply recombinant human erythropoietin.

Theoretically, using a dog or cat sequence to express the respective cat/dog epo should be easy, but are there any particular scientific hurdles you anticipate encountering in your effort? The fact that humans can also develop PRCA in response to Epo therapy suggests that there are additional factors independent of the peptide sequence that influence its immunogenicity.

Very cool. Thank you for your response Dr. Schatz. I apologize for not reading the description at the top of the page more carefully and simply assuming that you were trying to produce recombinant cat EPO. Do you anticipate that your compound(s) will also show EPO-R agonism in humans? For example, for use in patients who are at high risk of developing an autoimmune response to Epogen.

Lately I've been interested in the relationship between human and animal medicine, and how one side can help to inform the other. This interest was initially stimulated by this TED talk I saw last year: (http://www.ted.com/talks/barbara_natterson_horowitz_what_veterinarians_know_that_doctors_don_t). I feel that the world would have a lot less problems if we would start to see humans as animals, or animals as nonhuman persons (but thats outside the scope of this conversation).